Understanding the pathogenesis and clinical manifestations of systemic lupus
erythematosus (SLE) has been a great challenge. Reductionist approaches to understand …

Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted
therapy for cancer that has demonstrated notable potential in clinical applications. However …

Abstract The US Food and Drug Administration (FDA) has reported cases of T-cell
malignancies, including CAR-positive lymphomas, in patients receiving B cell maturation …

Aberrant immune responses to viral pathogens contribute to pathogenesis, but our
understanding of pathological immune responses caused by viruses within the human …

HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant
(HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following …

Abstract Human herpesvirus 6B (HHV-6B) reactivation and disease are increasingly
reported after chimeric antigen receptor (CAR) T-cell therapy (CARTx). HHV-6 reactivation in …

Background The implications of inherited chromosomally integrated human herpesvirus 6
(iciHHV-6) in solid organ transplantation remain uncertain. Although this trait has been …

Chimeric antigen receptor (CAR) T‐cell therapy, an innovative immunotherapeutic against
relapsed/refractory B‐cell lymphoma, faces challenges due to frequent viral infections …

Chimeric antigen receptor-modified T cell (CAR T-cell) therapy has revolutionized the
management of hematological malignancies. In addition to impressive malignancy-related …

Background Effective treatment options are scarce for relapsed or refractory T-cell
lymphoma. This study assesses the safety and activity of CTX130 (volamcabtagene …